SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00866762

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Phase II Study of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia.

The aim of the present study is to evaluate the efficacy and safety of MK-0683 in the treatment of PV and ET. This agent has most recently been shown to be a potent inhibitor of the autonomous proliferation of haematopoietic cells of PV and ET patients carrying the JAK2 V617F mutation. Accordingly, it may be anticipated that MK-0683 - by decreasing the JAK2 allele burden - may influence clonal myeloproliferation and in vivo granulocyte, platelet and endothelial activation , which are considered to be major determinants of morbidity and mortality ( thrombosis, bleeding, extramedullary haematopoiesis , myelofibrosis ) in these disorders. The effects of MK-0683 at the molecular level will be studied by global/ focused gene expression profiling, epigenome profiling and proteomics.

NCT00866762 Polycythemia Vera Essential Thrombocythemia
MeSH:Polycythemia Vera Polycythemia Thrombocytosis Thrombocythemia, Essential
HPO:Polycythemia Thrombocytosis

1 Interventions

Name: HDAC inhibitor (MK-0683)

Description: 400 mg once daily for 6 months
Type: Drug
Group Labels: 1

1


Primary Outcomes

Measure: To evaluate the efficacy of study drug (MK-0683) in the treatment of patients with PV and ET.

Time: one year

Secondary Outcomes

Measure: To study changes in bone marrow morphology before and after treatment with study drug.

Time: one year

Purpose: Treatment

Allocation: Non-Randomized

Single Group Assignment


There is one SNP

SNPs


1 V617F

This agent has most recently been shown to be a potent inhibitor of the autonomous proliferation of haematopoietic cells of PV and ET patients carrying the JAK2 V617F mutation. --- V617F ---



HPO Nodes


HPO: